Anti-NMDA Receptor Antibodies (Anti-NMDAR)
IgG autoantibodies directed against the GluN1 (NR1) subunit of the ionotropic N-methyl-D-aspartate (NMDA) glutamate receptor in the brain.
Standard vs. Optimal Reference RangesTiter
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Within standard population reference range, though above optimal longevity targets.
Negative (serum & CSF titer <1:1)
General reference distribution across unselected commercial populations.
Negative (undetectable)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds extracellular NMDA receptor domains, inducing receptor cross-linking, internalization, and catastrophic reduction in synaptic density.
Differential Diagnosis
Elevated Levels (Anti-NMDAR High)
- •Anti-NMDA Receptor Encephalitis (often secondary to occult ovarian teratoma)
- •Post-herpes simplex viral encephalitis autoimmune relapse
Low Levels (Anti-NMDAR Low)
- •Normal healthy blood-brain barrier and neuronal tolerance
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for Anti-NMDAR
- Targeted organ system imaging or functional dynamic testing related to autoimmune synaptic encephalitis
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Anti-NMDA Receptor Antibodies - The New England Journal of Medicine (2021). PMID: 34090124
- [2]Anti-NMDAR Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-NMDA Receptor Antibodies (Anti-NMDAR) into overall healthspan optimization.